arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Inhibikase Therapeutics, Inc.

IKT
$2.47 ▲ +0.05 (+2.07%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
26 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Inhibikase Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $425.6M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -8.4%
FCF / Share $-0.07
Trailing P/E
Price / Book 2.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-16.38M
↓ -19.8%
Operating Margin Operating profit as % of sales
-192.8%
↓ -3.4%
FCF / Share Free cash flow per share
$-0.07
↓ -52.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
24
Cash Quality
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters